Weight Loss Before Bariatric Surgery in T2DM: GLP-1 Agonist Gets it Done

February 2, 2015

Pre-surgical weight loss in obese patients with type 2 diabetes reduces perioperative risk. The dual benefits of GLP-1 agonists offer promise to this hard-to-treat population.

Bariatric surgery constitutes a powerful option to ameliorate severe obesity and type 2 diabetes. Given the growing global incidence of both chronic diseases, strategies that may augment the benefits of bariatric surgery in patients with obesity and type 2 diabetes need to be further explored. The current study is a profitable beginning.The slides above highlight a study in which the GLP-1 receptor agonist exenatide improved metabolic control and resulted in significant weight loss in obese patients with type 2 diabetes scheduled for bariatric surgery. SourceIglesias P, Civantos S, Vega B, et al. Clinical effectiveness of exanatide in diabetic patients waiting for bariatric surgery. Obes Surg. 2015;doi:10.1007/s11695-014-1563-9. (Subscription required)